An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Volasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 25 Aug 2017 Planned End Date changed from 1 Aug 2017 to 26 Aug 2022.
- 03 Jun 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2014 New trial record